Haematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia

Farhad Ravandi; Hagop Kantarjian

doi:10.1038/nrclinonc.2012.83

Haematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia

Farhad Ravandi, Hagop Kantarjian

Leukemia

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Gemtuzumab ozogamicin was withdrawn from the market after being evaluated in combination with chemotherapy in the frontline treatment of patients aged 18 to 60 years with acute myeloid leukaemia (AML). More-recent randomized trials demonstrate that low doses of gemtuzumab added to cytarabine and anthracycline-based chemotherapy benefit patients with better-risk AML.

Original language	English (US)
Pages (from-to)	310-311
Number of pages	2
Journal	Nature Reviews Clinical Oncology
Volume	9
Issue number	6
DOIs	https://doi.org/10.1038/nrclinonc.2012.83
State	Published - Jun 2012

ASJC Scopus subject areas

Oncology

Access to Document

10.1038/nrclinonc.2012.83

Cite this

@article{f50d3c9b569f4db9ad1ed3d7bb79ca95,

title = "Haematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia",

abstract = "Gemtuzumab ozogamicin was withdrawn from the market after being evaluated in combination with chemotherapy in the frontline treatment of patients aged 18 to 60 years with acute myeloid leukaemia (AML). More-recent randomized trials demonstrate that low doses of gemtuzumab added to cytarabine and anthracycline-based chemotherapy benefit patients with better-risk AML.",

author = "Farhad Ravandi and Hagop Kantarjian",

year = "2012",

month = jun,

doi = "10.1038/nrclinonc.2012.83",

language = "English (US)",

volume = "9",

pages = "310--311",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Haematological cancer

T2 - Gemtuzumab ozogamicin in acute myeloid leukaemia

AU - Ravandi, Farhad

AU - Kantarjian, Hagop

PY - 2012/6

Y1 - 2012/6

N2 - Gemtuzumab ozogamicin was withdrawn from the market after being evaluated in combination with chemotherapy in the frontline treatment of patients aged 18 to 60 years with acute myeloid leukaemia (AML). More-recent randomized trials demonstrate that low doses of gemtuzumab added to cytarabine and anthracycline-based chemotherapy benefit patients with better-risk AML.

AB - Gemtuzumab ozogamicin was withdrawn from the market after being evaluated in combination with chemotherapy in the frontline treatment of patients aged 18 to 60 years with acute myeloid leukaemia (AML). More-recent randomized trials demonstrate that low doses of gemtuzumab added to cytarabine and anthracycline-based chemotherapy benefit patients with better-risk AML.

UR - http://www.scopus.com/inward/record.url?scp=84861720251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861720251&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2012.83

DO - 10.1038/nrclinonc.2012.83

M3 - Review article

C2 - 22547217

AN - SCOPUS:84861720251

SN - 1759-4774

VL - 9

SP - 310

EP - 311

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 6

ER -

Haematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this